External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry

Arthur Darmon , Deepak Bhatt (1) , Yedid Elbez , Victor Aboyans (2, 3) , Sonia Anand (4) , Jackie Bosch (5) , Kelley Branch , Stuart Connolly , Leanne Dyal , John Eikelboom (6) , Keith A.A. Fox (7) , Katalin Keltai , Jeffrey Probstfield , Salim Yusuf (8) , Jérémie Abtan (9) , Emmanuel Sorbets (10) , Kim Eagle , Gregory Ducrocq (11) , Philippe Gabriel Steg (12)

1 VA Boston Healthcare System
2 Service de Chirurgie Thoracique et Vasculaire - Médecine vasculaire [CHU Limoges]
3 NET - Neuroépidémiologie Tropicale
4 Divisions of Cardiology and Thromboembolism McMaster University Hamiton
5 Population Health Research Institute
6 McMaster University [Hamilton, Ontario]
7 University of Edinburgh
8 Hamilton General Hospital
9 ICAN - Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases
10 Service de cardiologie
11 LBPC - Hémostase, bio-ingénierie et remodelage cardiovasculaires
12 Hôpital Bichat - Claude Bernard

The aims of the present study were to describe the proportion of patients eligible for the COMPASS trial within the Reduction of Atherothrombosis for Continued Health (REACH) registry, the reasons for ineligibility, and to put in perspective the characteristics and outcomes of trial-eligible patients from the REACH registry compared with those of patients enrolled in the reference aspirin arm of the COMPASS trial.

Domaines: Sciences du Vivant [q-bio]; Santé publique et épidémiologie

Arthur Darmon, Deepak Bhatt, Yedid Elbez, Victor Aboyans, Sonia Anand, et al.. External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. European Heart Journal, 2018, 39 (9), pp.750-757a. ⟨10.1093/eurheartj/ehx658⟩. ⟨hal-02043611⟩